SCHEMBL6850964

SCHEMBL6850964

Cc1ccc(-c2n[nH]cc2C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
MAPT P10636 2/20 0.44
HPGD P15428 1/20 0.44
ERBB2 P04626 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
MAPK1 P28482 2/20 0.42
ALDH1A1 P00352 1/20 0.42
DCUN1D1 Q96GG9 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
METAP2 P50579 1/20 0.39
METAP1 P53582 1/20 0.39
HTR1D P28221 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR1E P28566 1/20 0.39
HTR7 P34969 1/20 0.39
HTR2B P41595 1/20 0.39
HTR6 P50406 1/20 0.39
LMNA P02545 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15741508 0.83 NPC1 (0.43) MEN1KMT2AMAPTERBB2SMN1; SMN2
SCHEMBL3755589 0.83 IKBKB (0.41) HPGDERBB2MAPK1DCUN1D1TDP1
SCHEMBL3160320 0.83 MAPK14 (0.42) MEN1KMT2AERBB2SMN1; SMN2ALDH1A1
SCHEMBL2449809 0.83 ALOX15 (0.48) MEN1KMT2AMAPTHPGDSMN1; SMN2
SCHEMBL5223142 0.82 MEN1 (0.53) MEN1KMT2AMAPTHPGDMAPK1
SCHEMBL15186271 0.81 LMNA (0.40) MAPTHPGDALDH1A1TDP1LMNA
Hydrochloric Acid SCHEMBL30879670 0.80 MEN1 (0.51) MEN1KMT2AMAPTHPGDMAPK1
SCHEMBL14572024 0.80 ERBB2 (0.46) HPGDERBB2SMN1; SMN2TDP1LMNA
SCHEMBL15236244 0.79 MAP2K4 (0.33) MEN1KMT2A
SCHEMBL8806952 0.79 MAP2K4 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947717-B2 Inhibitors of lethal factor protease BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2011-05-24 US disclosed
US-20100016292-A1 INHIBITORS OF LETHAL FACTOR PROTEASE THE BURNHAM INSTITUTE (US) 2010-01-21 US disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US disclosed
CN-1154637-C Method for producing substituted pyrazoles �����ɷ� 2004-06-23 CN disclosed
EP-1021416-B1 METHOD FOR PRODUCING SUBSTITUTED PYRAZOLES BASF AG (DE) 2004-05-19 EP disclosed
US-6229022-B1 REACTING CARBONYL COMPOUNDS WITH HYDRAZINE, ITS HYDRATE OR SALTS IN THE PRESENCE OF SULFURIC ACID AND IODINE OR AN IODINE LIBERATING COMPOUND BASF AKTIENGESELLSCHAFT (DE) 2001-05-08 US disclosed
EP-1021416-A1 METHOD FOR PRODUCING SUBSTITUTED PYRAZOLES BASF AKTIENGESELLSCHAFT (DE) 2000-07-26 EP disclosed
CN-1261351-A Process for preparing substituted pyrazoles BASF AG (DE) 2000-07-26 CN disclosed
WO-1998058914-A1 METHOD FOR PRODUCING SUBSTITUTED PYRAZOLES BASF AKTIENGESELLSCHAFT (DE) 1998-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof BRAF, RAF1, ARAF MEN1 852/4885KMT2A 3435/4885MAPT 574/4885
US-20100016292-A1 INHIBITORS OF LETHAL FACTOR PROTEASE APAF1, F11, SERPINB1 MEN1 1839/4885KMT2A 3345/4885MAPT 2957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.